Tumor gene expression testing identifies women with certain early-stage breast cancers who can safely skip chemotherapy.
Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC.
For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib.
OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.
Pembrolizumab has shown activity against some lung cancer metastases in the brain, but responses can be discordant with extracranial tumor responses.
Obese patients survived longer during immune checkpoint blockade for metastatic lung cancer compared with underweight patients and those who lost weight during treatment.
In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.
The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS.
Unconventional strategies and targeted therapeutics may be required to overcome the adverse risks associated with TP53-mutated AML.
A simple blood draw to evaluate cfDNA might one day be used for early-stage lung cancer screening—if the mutational “noise” of normal aging can be addressed.